|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
ELV041492307 |
| 003 |
DE-627 |
| 005 |
20230624085446.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
180726s2018 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.pcd.2017.06.004
|2 doi
|
| 028 |
5 |
2 |
|a GBV00000000000080A.pica
|
| 035 |
|
|
|a (DE-627)ELV041492307
|
| 035 |
|
|
|a (ELSEVIER)S1751-9918(17)30092-X
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
4 |
|a 610
|q DE-600
|
| 082 |
0 |
4 |
|a 630
|q VZ
|
| 082 |
0 |
4 |
|a 640
|q VZ
|
| 082 |
0 |
4 |
|a 590
|q VZ
|
| 082 |
0 |
4 |
|a 610
|q VZ
|
| 082 |
0 |
4 |
|a 600
|q VZ
|
| 084 |
|
|
|a 50.70
|2 bkl
|
| 100 |
1 |
|
|a Thong, Ken Yan
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Clinical risk factors predicting genital fungal infections with sodium–glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit
|
| 264 |
|
1 |
|c 2018
|
| 300 |
|
|
|a 6
|
| 336 |
|
|
|a nicht spezifiziert
|b zzz
|2 rdacontent
|
| 337 |
|
|
|a nicht spezifiziert
|b z
|2 rdamedia
|
| 338 |
|
|
|a nicht spezifiziert
|b zu
|2 rdacarrier
|
| 520 |
|
|
|a • Dapaglilfozin, an SGLT2 inhibitor, increases the risk of genital fungal infections. • Women are at much greater risk of developing genital infections with dapagliflozin. • Patients with prior genital fungal infection are also at greater risk. • Higher baseline HbA1c or BMI did not increase treatment-related genital infections. • Rates of dapagliflozin discontinuation due to genital infections were low.
|
| 650 |
|
7 |
|a Genital fungal infection
|2 Elsevier
|
| 650 |
|
7 |
|a Dapagliflozin
|2 Elsevier
|
| 650 |
|
7 |
|a Thrush
|2 Elsevier
|
| 650 |
|
7 |
|a SGLT2 inhibitor
|2 Elsevier
|
| 650 |
|
7 |
|a Genital mycotic infection
|2 Elsevier
|
| 700 |
1 |
|
|a Yadagiri, Mahender
|4 oth
|
| 700 |
1 |
|
|a Barnes, Dennis Joseph
|4 oth
|
| 700 |
1 |
|
|a Morris, David Stuart
|4 oth
|
| 700 |
1 |
|
|a Chowdhury, Tahseen Ahmad
|4 oth
|
| 700 |
1 |
|
|a Chuah, Ling Ling
|4 oth
|
| 700 |
1 |
|
|a Robinson, Anthony Michael
|4 oth
|
| 700 |
1 |
|
|a Bain, Stephen Charles
|4 oth
|
| 700 |
1 |
|
|a Adamson, Karen Ann
|4 oth
|
| 700 |
1 |
|
|a Ryder, Robert Elford John
|4 oth
|
| 773 |
0 |
8 |
|i Enthalten in
|n Elsevier
|a David, Lauren A. ELSEVIER
|t A pilot randomized controlled trial examining the feasibility, acceptability, and efficacy of Adapted Motivational Interviewing for post-operative bariatric surgery patients
|d 2016
|g Amsterdam [u.a.]
|w (DE-627)ELV024210129
|
| 773 |
1 |
8 |
|g volume:12
|g year:2018
|g number:1
|g pages:45-50
|g extent:6
|
| 856 |
4 |
0 |
|u https://doi.org/10.1016/j.pcd.2017.06.004
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_U
|
| 912 |
|
|
|a GBV_ELV
|
| 912 |
|
|
|a SYSFLAG_U
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_227
|
| 912 |
|
|
|a GBV_ILN_350
|
| 936 |
b |
k |
|a 50.70
|j Energie: Allgemeines
|q VZ
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 12
|j 2018
|e 1
|h 45-50
|g 6
|
| 953 |
|
|
|2 045F
|a 610
|